Companies Accendra Health Inc/VA/
Accendra Health Inc/VA/ (ACH): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Accendra Health Inc/VA/’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO vs. named peers36th pct.Of 14 peer CEOs
CEO pay, last three years
- $8,389,910FY2023
- $10,737,904FY2024
- $11,157,809FY2025
CEO total pay was $11,157,809 in fiscal 2025, up from $10,737,904 in fiscal 2024.
FY2025: salary $1,150,000 · stock awards $9,560,140
Executives and directors
Andrew Long · EVPPerry Bernocchi · COOEdward Pesicka · CEOHeath Galloway · General CounselJonathan Leon · CFOCarissa L. Rollins · Independent DirectorGwendolyn M. Bingham · Independent DirectorKenneth Gardner-Smith · Independent DirectorMark A. Beck · Chair of the BoardRita F. Johnson-Mills · Independent DirectorRobert J. Henkel · Independent DirectorStephen W. Klemash · Independent DirectorTeresa L. Kline · Independent Director
Frequently asked questions
Who was the highest-paid executive at Accendra Health Inc/VA/ in fiscal 2025?
As disclosed, Edward Pesicka (President & Chief Executive Officer) was the highest-paid executive at Accendra Health Inc/VA/ in fiscal 2025, with total compensation of $11,157,809.
How does Accendra Health Inc/VA/'s chief executive pay compare to its disclosed peer group?
As disclosed, Edward Pesicka's total compensation ranked at the 36th percentile of Accendra Health Inc/VA/'s disclosed peer group.
What is Accendra Health Inc/VA/'s CEO-to-median employee pay ratio?
As disclosed, Accendra Health Inc/VA/'s CEO-to-median employee pay ratio was 272:1.
How did shareholders vote on Accendra Health Inc/VA/'s executive compensation?
As disclosed, 91.92% of shareholders supported Accendra Health Inc/VA/'s executive compensation in the latest say-on-pay vote.
How much does Accendra Health Inc/VA/ spend in total on board compensation for fiscal 2025?
As disclosed, Accendra Health Inc/VA/ reported total board compensation of $2,850,000 for fiscal 2025.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Edward Pesicka | $1,150,000 | — | $9,560,140 | — | $345,000 | — | $102,669 | $11,157,809 |
| President & Chief Executive Officer | ||||||||
| Andrew Long | 691,866 | — | 2,879,578 | — | — | — | 15,736 | 3,587,180 |
| Executive Vice President, Chief Executive Officer, Products & Healthcare Services | ||||||||
| Perry Bernocchi | 644,417 | — | 2,649,205 | — | 119,070 | — | 10,913 | 3,423,605 |
| Executive Vice President, Chief Operating Officer | ||||||||
| Jonathan Leon | 572,885 | 300,000 | 2,073,293 | — | — | — | 16,528 | 2,962,706 |
| Executive Vice President & Chief Financial Officer | ||||||||
| Heath Galloway | 513,731 | 265,000 | 1,497,382 | — | — | — | 18,493 | 2,294,606 |
| Executive Vice President, General Counsel & Corporate Secretary | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Edward Pesicka | $11,157,809 | $10,737,904 | $8,389,910 | ↑ +419,905 |
| Andrew Long | 3,587,180 | 4,026,436 | 4,724,545 | ↓ −439,256 |
| Perry Bernocchi | 3,423,605 | 3,652,733 | 3,190,882 | ↓ −229,128 |
| Jonathan Leon | 2,962,706 | 2,290,912 | — | ↑ +671,794 |
| Heath Galloway | 2,294,606 | 2,171,221 | — | ↑ +123,385 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
Our executive compensation programs are designed to reflect a pay-for-performance philosophy that aligns with the business’s strategy and goals, both short and long-term, and pays for sustained performance, profitable growth, and achievement of results. We generally target the 50th percentile of our peer group and the relevant market as a reference point for positioning target total compensation for our executives, with the ability to earn above or below the 50th percentile based on Company and/or individual performance.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Frederic W. Cook & Co., Inc. (FW Cook) |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Jonathan Leon | RSU | 2025-03-03 | — | — | 96,576 | — | $900,004 |
| Perry Bernocchi | RSU | 2025-03-03 | — | — | 123,391 | — | 1,150,004 |
| Heath Galloway | RSU | 2025-03-03 | — | — | 69,743 | — | 650,005 |
| Edward Pesicka | PSU | 2025-03-03 | 222,640 | 445,279 | — | 890,558 | 5,410,140 |
| Andrew Long | RSU | 2025-03-03 | — | — | 134,121 | — | 1,250,008 |
| Perry Bernocchi | PSU | 2025-03-03 | 61,696 | 123,391 | — | 246,782 | 1,499,201 |
| Heath Galloway | PSU | 2025-03-03 | 34,872 | 69,743 | — | 139,486 | 847,377 |
| Andrew Long | PSU | 2025-03-03 | 67,061 | 134,121 | — | 268,242 | 1,629,570 |
| Edward Pesicka | RSU | 2025-03-03 | — | — | 445,279 | — | 4,150,000 |
| Jonathan Leon | PSU | 2025-03-03 | 48,284 | 96,567 | — | 193,134 | 1,173,289 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Jonathan Leon | $900,004 | $1,173,289 | $0 | 56.6% |
| Perry Bernocchi | 1,150,004 | 1,499,201 | 0 | 56.6% |
| Heath Galloway | 650,005 | 847,377 | 0 | 56.6% |
| Edward Pesicka | 4,150,000 | 5,410,140 | 0 | 56.6% |
| Andrew Long | 1,250,008 | 1,629,570 | 0 | 56.6% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Heath Galloway | RSU | 3,207 | — | $8,980 |
| Jonathan Leon | RSU | 5,879 | — | 16,461 |
| Heath Galloway | RSU | 6,050 | — | 16,940 |
| Jonathan Leon | PSU | 7,306 | — | 20,457 |
| Jonathan Leon | RSU | 11,421 | — | 31,979 |
| Heath Galloway | RSU | 16,316 | — | 45,685 |
| Jonathan Leon | PSU | 17,811 | — | 49,871 |
| Jonathan Leon | RSU | 19,202 | — | 53,766 |
| Perry Bernocchi | RSU | 21,374 | — | 59,847 |
| Heath Galloway | PSU | 24,351 | — | 68,183 |
| Jonathan Leon | RSU | 28,766 | — | 80,545 |
| Perry Bernocchi | RSU | 29,911 | — | 83,751 |
| Andrew Long | RSU | 33,990 | — | 95,172 |
| Perry Bernocchi | PSU | 44,643 | — | 125,000 |
| Andrew Long | RSU | 45,953 | — | 128,668 |
| Andrew Long | PSU | 50,731 | — | 142,047 |
| Edward Pesicka | RSU | 58,777 | — | 164,576 |
| Perry Bernocchi | PSU | 64,767 | — | 181,348 |
| Heath Galloway | RSU | 69,743 | — | 195,280 |
| Heath Galloway | PSU | 69,743 | — | 195,280 |
| Andrew Long | PSU | 74,482 | — | 208,550 |
| Heath Galloway | PSU | 94,094 | — | 263,463 |
| Heath Galloway | RSU | 95,316 | — | 266,885 |
| Jonathan Leon | RSU | 96,567 | — | 270,388 |
| Jonathan Leon | PSU | 96,567 | — | 270,388 |
| Edward Pesicka | RSU | 99,250 | — | 277,900 |
| Jonathan Leon | PSU | 121,684 | — | 340,716 |
| Perry Bernocchi | RSU | 123,391 | — | 345,495 |
| Perry Bernocchi | PSU | 123,391 | — | 345,495 |
| Andrew Long | RSU | 134,121 | — | 375,539 |
| Andrew Long | PSU | 134,121 | — | 375,539 |
| Edward Pesicka | PSU | 148,134 | — | 414,775 |
| Jonathan Leon | RSU | 161,835 | — | 453,139 |
| Perry Bernocchi | RSU | 174,676 | — | 489,093 |
| Edward Pesicka | PSU | 178,109 | — | 498,705 |
| Andrew Long | RSU | 214,064 | — | 599,379 |
| Perry Bernocchi | PSU | 232,801 | — | 651,843 |
| Andrew Long | PSU | 259,334 | — | 726,136 |
| Edward Pesicka | RSU | 445,279 | — | 1,246,781 |
| Edward Pesicka | PSU | 445,279 | — | 1,246,781 |
| Edward Pesicka | RSU | 603,306 | — | 1,689,257 |
| Edward Pesicka | PSU | 771,522 | — | 2,160,261 |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Mark A. BeckIndependent · Board Chair · Executive (Chair) · Governance Nominating | $255,000 | $205,000 | — | — | — | $460,000 |
| Stephen W. KlemashIndependent · Audit (Chair) · Executive | 155,000 | 205,000 | — | — | — | 360,000 |
| Gwendolyn M. BinghamIndependent · Executive · Governance Nominating (Chair) | 150,000 | 205,000 | — | — | — | 355,000 |
| Kenneth Gardner-SmithIndependent · Executive | 143,750 | 205,000 | — | — | — | 348,750 |
| Robert J. HenkelIndependent · Not standing for re-election | 131,250 | 205,000 | — | — | — | 336,250 |
| Carissa L. RollinsIndependent · Audit · Not standing for re-election | 125,000 | 205,000 | — | — | — | 330,000 |
| Rita F. Johnson-MillsIndependent · Governance Nominating · Not standing for re-election | 125,000 | 205,000 | — | — | — | 330,000 |
| Teresa L. KlineIndependent · Audit | 125,000 | 205,000 | — | — | — | 330,000 |
| Edward A. PesickaEmployee director · Executive | — | — | — | — | — | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $125,000 |
|---|---|
| Annual equity retainer | $205,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 30,000 / 25,000 / 25,000 |
| Stock ownership guideline | $4 |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $1,210,000 |
| Equity awards (grant-date value) | $1,640,000 |
| All other compensation | $0 |
| Total cost of the board | $2,850,000 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Accendra Health Inc/VA/ as a peer
Companies that benchmark against ACH
12 companies name ACH as a compensation peer
The list of companies that name ACH as a peer is temporarily unavailable — recheck shortly.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
AHCO AdaptHealth Corp.BSX Boston Scientific CorporationPDCO Patterson Companies, Inc.BAX Baxter International Inc.RMD ResMed Inc.CHRW C.H. Robinson Worldwide, Inc.SEM Select Medical Holdings CorporationXRAY DENTSPLY SIRONA Inc.STE STERIS plcHSIC Henry Schein, Inc.WCC WESCO International, Inc.HOLX Hologic, Inc.ZBH Zimmer Biomet Holdings, Inc.DGX Quest Diagnostics Incorporated
Peer reciprocity
The companies Accendra Health Inc/VA/ names as compensation peers that name it back in their own disclosed peer groups.
AdaptHealth Corp. (AHCO)59Patterson Companies, Inc. (PDCO)60Henry Schein, Inc. (HSIC)61Quest Diagnostics Incorporated (DGX)62
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Baxter International Inc. | 2025 | Andrew Hider | $499,315 | $23,133,518 | $3,185,053 | $820,125 | $29,805,182 |
| 2 | Boston Scientific Corporation | 2025 | Michael Mahoney | 1,442,603 | 13,608,056 | 3,749,980 | 4,002,001 | 23,532,050 |
| 3 | ResMed Inc. | 2026 | Michael Farrell | 1,272,895 | 9,749,468 | 3,249,907 | 1,738,857 | 16,201,649 |
| 4 | Zimmer Biomet Holdings, Inc. | 2025 | Ivan Tornos | 1,281,846 | 12,000,101 | 0 | 2,420,767 | 16,106,550 |
| 5 | Hologic, Inc. | 2024 | Stephen MacMillan | 1,212,628 | 9,141,468 | 2,937,477 | 1,990,413 | 15,819,261 |
| 6 | Quest Diagnostics Incorporated | 2025 | James Davis | 1,250,000 | 8,762,861 | 2,999,873 | 2,205,844 | 15,498,479 |
| 7 | Wesco International, Inc. | 2025 | John Engel | 1,412,165 | 7,112,936 | 2,275,029 | 1,362,550 | 12,308,746 |
| 8 | Henry Schein, Inc. | 2025 | Stanley Bergman | 1,707,000 | 7,764,800 | 0 | 2,289,251 | 12,013,915 |
| 9 | Steris plc | 2026 | Daniel Carestio | 1,095,707 | 4,333,951 | 4,334,251 | 1,725,007 | 11,508,522 |
| 10 | Accendra Health Inc/VA/ | 2025 | Edward Pesicka | 1,150,000 | 9,560,140 | — | 345,000 | 11,157,809 |
| 11 | C.H. Robinson Worldwide, Inc. | 2025 | David Bozeman | 1,100,962 | 6,984,383 | 0 | 2,879,618 | 11,045,949 |
| 12 | AdaptHealth Corp. | 2025 | Suzanne Foster | 1,000,000 | 7,530,880 | 0 | 1,394,694 | 10,256,240 |
| 13 | Dentsply Sirona Inc. | 2025 | Daniel Scavilla | 431,753 | 3,484,488 | 3,221,523 | 437,150 | 8,760,139 |
| 14 | Patterson Companies, Inc. | 2024 | Donald Zurbay | 900,001 | 3,063,124 | 1,000,000 | 813,713 | 5,895,511 |
| 15 | Select Medical Holdings Corporation | 2025 | Thomas Mullin | 618,000 | 1,425,000 | 0 | 939,360 | 3,042,527 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Accendra Health Inc/VA/ | 20% | RSU 50 · PSU 50 | not disclosed | Frederic W. Cook & Co., Inc. (FW Cook) |
| AdaptHealth Corp. | 116.22% | PSU 50 · RSU 50 | Yes — Relative TSR | ClearBridge |
| Baxter International Inc. | not disclosed | PSU 50 · RSU 25 · Option 25 | No | Aon |
| Boston Scientific Corporation | 173% | PSU 50 · RSU 25 · Options 25 | No | Semler Brossy Consulting Group, LLC |
| C.H. Robinson Worldwide, Inc. | 171% | PSU 60 · RSU 40 | No | Semler Brossy |
| Dentsply Sirona Inc. | 66% | PSU 50 · Options 50 | No | Frederic W. Cook & Co., Inc. |
| Henry Schein, Inc. | 89.3% | PSU 65 · RSU 35 | No | Pearl Meyer |
| Hologic, Inc. | 109% | PSU 50 · RSU 25 · Option 25 | No | Pearl Meyer & Partners, LLC |
| Patterson Companies, Inc. | 72.33% | PSU 50 · Options 25 · RSU 25 | No | Semler Brossy |
| Quest Diagnostics Incorporated | 113.9% | PSU 50 · RSU 25 · Options 25 | Yes — Relative TSR | Semler Brossy |
| ResMed Inc. | not disclosed | PSU 50 · RSU 25 · Options 25 | Yes — Relative TSR | FW Cook |
| Select Medical Holdings Corporation | 190% | RSU 100 | not disclosed | not disclosed |
| Steris plc | 125.1% | Option 50 · Restricted Stock 50 | not disclosed | Frederic W. Cook & Co., Inc. |
| Wesco International, Inc. | not disclosed | not disclosed | Yes — Relative Total Stockholder Return (TSR) Modifier | Meridian Compensation Partners, LLC |
| Zimmer Biomet Holdings, Inc. | 125.9% | RSU 50 · PSU 50 | Yes — Relative TSR | Semler Brossy |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-05-14 | 48,137,834 | 4,098,288 | 134,341 | 91.92% | Passed |
| 2025 | 2025-05-15 | 63,157,616 | 3,148,361 | 72,234 | 95.25% | Passed |
| 2024 | 2024-05-09 | 66,163,767 | 1,381,531 | 60,198 | 97.95% | Passed |
| 2023 | 2023-05-11 | 66,736,433 | 2,218,092 | 52,268 | 96.78% | Passed |
| 2022 | 2022-04-29 | 62,995,756 | 2,479,032 | 89,896 | 96.21% | Passed |
| 2021 | 2021-04-29 | 60,758,216 | 1,089,362 | 109,738 | 98.24% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-05-14 | 91.92%a |
| 2025 | 2025-05-15 | 95.25%b |
| 2024 | 2024-05-09 | 97.95%c |
a. Approved under the standard stated in the filing — “Abstentions are counted for purposes of determining whether a quorum is present and will have the same effect as a vote "against" the proposal.”.
b. Approved under the standard stated in the filing — “Abstentions and broker non-votes will not be counted as votes cast on this proposal and will have no effect on the results of this vote.”.
c. Approved under the standard stated in the filing — “Abstentions will not be counted as votes cast on this proposal and will have no effect on the results of this vote.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | 272 : 1 |
|---|---|
| CEO total compensation | $11,157,809 |
| Median employee compensation | $41,005 |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Gwendolyn M. Bingham | Director | 2026-05-14 | A | 31,191 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| Teresa L. Kline | Director | 2026-05-14 | A | 31,191 | 0 | 0 | Common | Form 4 ↗ |
| Mark A. Beck | Director | 2026-05-14 | A | 31,191 | 0 | 0 | Common | Form 4 ↗ |
| Kenneth Gardner-Smith | Director | 2026-05-14 | A | 31,191 | 0 | 0 | Common | Form 4 ↗ |
| Stephen W. Klemash | Director | 2026-05-14 | A | 31,191 | 0 | 0 | Common | Form 4 ↗ |
| Heath Galloway | EVP,General Counsel & CorpSecy | 2026-05-15 | D | 966 | 3 | 2,937 | Common | Form 4 ↗ |
| Edward A. Pesicka | Director | 2026-05-15 | D | 17,692 | 3 | 53,784 | Common | Form 4 ↗ |
| Jonathan Leon | EVP & CFO | 2026-05-15 | D | 1,770 | 3 | 5,381 | Common | Form 4 ↗ |
| Perry Bernocchi | EVP, Chief Operating Officer | 2026-05-15 | D | 7,908 | 3 | 24,040 | Common | Form 4 ↗ |
| Heath Galloway | EVP,General Counsel & CorpSecy | 2026-05-18 | D | 1,822 | 3 | 5,302 | Common | Form 4 ↗ |
| Jonathan Leon | EVP & CFO | 2026-09-23 | D | 4,265 | 1 | 3,625 | Common | Form 4 ↗ |
| Kenneth Gardner-Smith | Director | 2026-10-05 | A | 283,554 | 0 | 0 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (62 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Edward Pesicka. DEF 14A, filed 2026-04-02. Section “2025 Summary Compensation Table” · page 46. As printed: 11,157,809. View filing ↗
- Section 01, Andrew Long. DEF 14A, filed 2026-04-02. Section “2025 Summary Compensation Table” · page 46. As printed: 3,587,180. View filing ↗
- Section 01, Perry Bernocchi. DEF 14A, filed 2026-04-02. Section “2025 Summary Compensation Table” · page 46. As printed: 3,423,605. View filing ↗
- Section 01, Jonathan Leon. DEF 14A, filed 2026-04-02. Section “2025 Summary Compensation Table” · page 46. As printed: 2,962,706. View filing ↗
- Section 01, Heath Galloway. DEF 14A, filed 2026-04-02. Section “2025 Summary Compensation Table” · page 46. As printed: 2,294,606. View filing ↗
- Section 03, Jonathan Leon RSU. DEF 14A, filed 2026-04-02. Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Perry Bernocchi RSU. DEF 14A, filed 2026-04-02. Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Heath Galloway RSU. DEF 14A, filed 2026-04-02. Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Edward Pesicka PSU. DEF 14A, filed 2026-04-02. Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Andrew Long RSU. DEF 14A, filed 2026-04-02. Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Perry Bernocchi PSU. DEF 14A, filed 2026-04-02. Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Heath Galloway PSU. DEF 14A, filed 2026-04-02. Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Andrew Long PSU. DEF 14A, filed 2026-04-02. Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Edward Pesicka RSU. DEF 14A, filed 2026-04-02. Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Jonathan Leon PSU. DEF 14A, filed 2026-04-02. Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2026-04-02. Section “CEO Pay Ratio”. As printed: 272 : 1. View filing ↗
- Section 08, Mark A. Beck. DEF 14A, filed 2026-04-02. Section “Director Compensation”. As printed: 460,000. View filing ↗
- Section 08, Stephen W. Klemash. DEF 14A, filed 2026-04-02. Section “Director Compensation”. As printed: 360,000. View filing ↗
- Section 08, Gwendolyn M. Bingham. DEF 14A, filed 2026-04-02. Section “Director Compensation”. As printed: 355,000. View filing ↗
- Section 08, Kenneth Gardner-Smith. DEF 14A, filed 2026-04-02. Section “Director Compensation”. As printed: 348,750. View filing ↗
- Section 08, Robert J. Henkel. DEF 14A, filed 2026-04-02. Section “Director Compensation”. As printed: 336,250. View filing ↗
- Section 08, Carissa L. Rollins. DEF 14A, filed 2026-04-02. Section “Director Compensation”. As printed: 330,000. View filing ↗
- Section 08, Rita F. Johnson-Mills. DEF 14A, filed 2026-04-02. Section “Director Compensation”. As printed: 330,000. View filing ↗
- Section 08, Teresa L. Kline. DEF 14A, filed 2026-04-02. Section “Director Compensation”. As printed: 330,000. View filing ↗
- Section 08, Edward A. Pesicka. DEF 14A, filed 2026-04-02. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Gwendolyn M. Bingham 2026-05-14. Form 4, filed 2026-05-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Teresa L. Kline 2026-05-14. Form 4, filed 2026-05-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark A. Beck 2026-05-14. Form 4, filed 2026-05-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kenneth Gardner-Smith 2026-05-14. Form 4, filed 2026-05-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Stephen W. Klemash 2026-05-14. Form 4, filed 2026-05-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Heath Galloway 2026-05-15. Form 4, filed 2026-05-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Edward A. Pesicka 2026-05-15. Form 4, filed 2026-05-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jonathan Leon 2026-05-15. Form 4, filed 2026-05-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Perry Bernocchi 2026-05-15. Form 4, filed 2026-05-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Heath Galloway 2026-05-18. Form 4, filed 2026-05-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jonathan Leon 2026-09-23. Form 4, filed 2026-09-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kenneth Gardner-Smith 2026-10-05. Form 4, filed 2026-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-05-15. Item 5.07 · say-on-pay result. As reported: 91.92% (votes for as printed: 48,137,834). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-05-16. Item 5.07 · say-on-pay result. As reported: 95.25% (votes for as printed: 63,157,616). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-05-10. Item 5.07 · say-on-pay result. As reported: 97.95% (votes for as printed: 66,163,767). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 1,210,000 + equity 1,640,000 + all other 0 = 2,850,000, summed across the director compensation table rows.
- Baxter International Inc., Section 10b CEO total. DEF 14A, filed 2026-03-23. CEO total compensation as printed in Baxter International Inc.'s own proxy. As printed: 29,805,182. View filing ↗
- Boston Scientific Corporation, Section 10b CEO total. DEF 14A, filed 2026-03-18. CEO total compensation as printed in Boston Scientific Corporation's own proxy. As printed: 23,532,050. View filing ↗
- ResMed Inc., Section 10b CEO total. DEF 14A, filed 2026-10-01. CEO total compensation as printed in ResMed Inc.'s own proxy. As printed: 16,201,649. View filing ↗
- Zimmer Biomet Holdings, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-01. CEO total compensation as printed in Zimmer Biomet Holdings, Inc.'s own proxy. As printed: 16,106,550. View filing ↗
- Hologic, Inc., Section 10b CEO total. DEF 14A, filed 2025-01-16. CEO total compensation as printed in Hologic, Inc.'s own proxy. As printed: 15,819,261. View filing ↗
- Quest Diagnostics Incorporated, Section 10b CEO total. DEF 14A, filed 2026-04-06. CEO total compensation as printed in Quest Diagnostics Incorporated's own proxy. As printed: 15,498,479. View filing ↗
- Wesco International, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-17. CEO total compensation as printed in Wesco International, Inc.'s own proxy. As printed: 12,308,746. View filing ↗
- Henry Schein, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-08. CEO total compensation as printed in Henry Schein, Inc.'s own proxy. As printed: 12,013,915. View filing ↗
- Steris plc, Section 10b CEO total. DEF 14A, filed 2026-06-11. CEO total compensation as printed in Steris plc's own proxy. As printed: 11,508,522. View filing ↗
- Accendra Health Inc/VA/ (subject), Section 10b CEO total. DEF 14A, filed 2026-04-02. CEO total compensation as printed in Accendra Health Inc/VA/'s own proxy. As printed: 11,157,809. View filing ↗
- C.H. Robinson Worldwide, Inc., Section 10b CEO total. DEF 14A, filed 2026-03-24. CEO total compensation as printed in C.H. Robinson Worldwide, Inc.'s own proxy. As printed: 11,045,949. View filing ↗
- AdaptHealth Corp., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in AdaptHealth Corp.'s own proxy. As printed: 10,256,240. View filing ↗
- Dentsply Sirona Inc., Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Dentsply Sirona Inc.'s own proxy. As printed: 8,760,139. View filing ↗
- Patterson Companies, Inc., Section 10b CEO total. DEF 14A, filed 2024-08-02. CEO total compensation as printed in Patterson Companies, Inc.'s own proxy. As printed: 5,895,511. View filing ↗
- Select Medical Holdings Corporation, Section 10b CEO total. DEF 14A, filed 2026-03-04. CEO total compensation as printed in Select Medical Holdings Corporation's own proxy. As printed: 3,042,527. View filing ↗
- Section 10a, AdaptHealth Corp. reciprocity. DEF 14A. AdaptHealth Corp. names Accendra Health Inc/VA/ in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Patterson Companies, Inc. reciprocity. DEF 14A. Patterson Companies, Inc. names Accendra Health Inc/VA/ in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Henry Schein, Inc. reciprocity. DEF 14A. Henry Schein, Inc. names Accendra Health Inc/VA/ in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Quest Diagnostics Incorporated reciprocity. DEF 14A. Quest Diagnostics Incorporated names Accendra Health Inc/VA/ in its own disclosed peer group (read from its most recent proxy). View filing ↗